Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Summary

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical or uncommon activating EGFR mutations. Efficacy of dacomitinib will be defined in patients with asymptomatic or controlled brain metastases, special population eligible in this clinical trial.

Timeline

Start

2020-06-12

Primary completion

2023-12-31

Completion

2023-12-31

Drugs

Indications